Want to see TSE:RX full AI Analyst Report?
RX Stock Chart & Stats
C$14.74
-C$0.09(-0.61%)
At close: 4:00 PM EDT
C$14.74
-C$0.09(-0.61%)
Day’s Range― - ―
52-Week RangeC$10.65 - C$15.80
Previous CloseN/A
Volume2.74K
Average Volume (3M)5.67K
Market Cap
C$167.00M
Enterprise ValueC$161.58
Total Cash (Recent Filing)C$10.90M
Total Debt (Recent Filing)C$5.25M
Price to Earnings (P/E)18.0
Beta0.80
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.44%
Share Statistics
EPS (TTM)0.81
Shares Outstanding11,438,318
10 Day Avg. Volume6,048
30 Day Avg. Volume5,666
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)3.46
Price to Sales (P/S)3.33
P/FCF Ratio14.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$18.00Price Target Upside22.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.89
Revenue Forecast (FY)C$68.60M
Bulls Say, Bears Say
Bulls Say
High Margins And ProfitabilityVery high gross and operating margins give Biosyent a strong earnings base and help absorb product, distribution, and commercialization costs. Sustained profitability also supports reinvestment, licensing activity, and resilience if individual products face pressure.
Conservative Balance SheetMinimal leverage reduces refinancing risk and preserves financial flexibility for product acquisitions, licensing investments, and operating needs. Improving returns on equity indicate that Biosyent is generating stronger shareholder returns without relying heavily on debt.
Strong Operating Cash GenerationOperating cash flow above reported earnings supports the quality of Biosyent’s profits, while the TTM free-cash-flow rebound improves funding capacity. This can support dividends, portfolio expansion, and commercial investment with less dependence on external capital.
Bears Say
Uneven Revenue GrowthThe company’s growth record is not consistently linear, indicating that product launches, demand, or portfolio changes can materially affect annual results. Uneven expansion makes it harder to rely on a steady scaling trajectory over the next several reporting periods.
Free-cash-flow VolatilityAlthough recent cash generation is strong, the prior free-cash-flow shortfall shows that working-capital movements or investment timing can materially affect liquidity. Such variability may complicate planning for acquisitions, shareholder returns, and ongoing commercialization needs.
Gross-margin CompressionThe lower TTM gross margin suggests some erosion in product mix, pricing, or supply economics compared with prior years. If the trend persists, it could reduce operating leverage and limit the amount of revenue converted into reinvestment and profit.
RX FAQ
What was Biosyent Inc’s price range in the past 12 months?
Biosyent Inc lowest stock price was C$10.65 and its highest was C$15.80 in the past 12 months.
What is Biosyent Inc’s market cap?
Biosyent Inc’s market cap is C$167.00M.
When is Biosyent Inc’s upcoming earnings report date?
Biosyent Inc’s upcoming earnings report date is Aug 20, 2026 which is tomorrow.
How were Biosyent Inc’s earnings last quarter?
Biosyent Inc released its earnings results on May 14, 2026. The company reported C$0.2 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Biosyent Inc overvalued?
According to Wall Street analysts Biosyent Inc’s price is currently Undervalued.
Does Biosyent Inc pay dividends?
Biosyent Inc pays a Quarterly dividend of C$0.055 which represents an annual dividend yield of 1.44%. See more information on Biosyent Inc dividends here
What is Biosyent Inc’s EPS estimate?
Biosyent Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biosyent Inc have?
Biosyent Inc has 11,438,318 shares outstanding.
What happened to Biosyent Inc’s price movement after its last earnings report?
Biosyent Inc reported an EPS of C$0.2 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.07%.
Which hedge fund is a major shareholder of Biosyent Inc?
Currently, no hedge funds are holding shares in TSE:RX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biosyent Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$18.00 (22.12% Upside)
C$18.00 (22.12% Upside)
Insider Transactions
Sold Shares
Worth C$310.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.79%
12-Months-Change
Fundamentals
Return on Equity
1.44%
Trailing 12-Months
Asset Growth
46.14%
Trailing 12-Months
Company Description
Biosyent Inc
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. BioSyent Inc. was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. The company was incorporated in 2006 and is headquartered in Mississauga, Canada.
RX Stock 12 Month Forecast
Average Price Target
C$18.00
▲(22.12% Upside)
Technical Analysis
Aequus Pharmaceuticals
―
Willow Biosciences Inc
―
Medexus Pharmaceuticals Inc
―
HLS Therapeutics Inc
―
Cardiol Therapeutics
―